Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBITDA Margin: 2019-2023

Historic EBITDA Margin for Benitec Biopharma (BNTC) over the last 2 years, with Jun 2023 value amounting to -66,257.14%.

  • Benitec Biopharma's EBITDA Margin was N/A to -66,257.14% in Q2 2023 from the same period last year, while for Jun 2023 it was -15,566.67%, marking a year-over-year change of. This contributed to the annual value of -25,529.33% for FY2023, which is 87454.00% down from last year.
  • Per Benitec Biopharma's latest filing, its EBITDA Margin stood at -66,257.14% for Q2 2023, which was down 722.12% from -8,059.26% recorded in Q1 2023.
  • Over the past 5 years, Benitec Biopharma's EBITDA Margin peaked at 6,157.14% during Q2 2020, and registered a low of -393,300.00% during Q1 2021.
  • In the last 3 years, Benitec Biopharma's EBITDA Margin had a median value of -39,792.86% in 2022 and averaged -103,939.94%.
  • In the last 5 years, Benitec Biopharma's EBITDA Margin tumbled by 38,257,500bps in 2021 and then surged by 38,599,167bps in 2022.
  • Over the past 5 years, Benitec Biopharma's EBITDA Margin (Quarterly) stood at -2,277.92% in 2019, then plummeted by 30,212,208bps to -304,400.00% in 2020, then skyrocketed by 28,488,800bps to -19,512.00% in 2021, then crashed by 2,028,086bps to -39,792.86% in 2022, then crashed by 75,093bps to -66,257.14% in 2023.
  • Its EBITDA Margin stands at -66,257.14% for Q2 2023, versus -8,059.26% for Q1 2023 and -39,792.86% for Q4 2022.